Imunon reports Q3 EPS ($1.16) vs ($3.76) last year

“IMUNON (IMNN) is rapidly advancing a potential breakthrough for women with newly diagnosed advanced ovarian cancer-a disease with no meaningful frontline treatment progress in decades,” said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. “Strong Phase 2 OVATION 2 survival data, reinforced by compelling interim results from our MRD study and a clear regulatory path in Phase 3, position IMNN-001 to deliver transformative impact.”